VYNE Therapeutics (NASDAQ:VYNE) Rating Lowered to Sell at Wall Street Zen

VYNE Therapeutics (NASDAQ:VYNE) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $4.50.

VYNE Therapeutics Stock Up 0.1%

VYNE Therapeutics stock opened at $0.58 on Friday. The firm has a 50 day moving average price of $0.48 and a 200-day moving average price of $0.50. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $3.00. The company has a market capitalization of $19.32 million, a P/E ratio of -0.74 and a beta of 1.95.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million. Equities analysts expect that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Baker BROS. Advisors LP purchased a new position in VYNE Therapeutics during the third quarter worth about $285,000. Adage Capital Partners GP L.L.C. boosted its position in shares of VYNE Therapeutics by 87.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after acquiring an additional 300,000 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in shares of VYNE Therapeutics during the second quarter worth about $942,000. Shay Capital LLC purchased a new position in shares of VYNE Therapeutics during the third quarter worth about $165,000. Finally, Patient Square Capital LP increased its position in shares of VYNE Therapeutics by 23.3% in the second quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock worth $523,000 after purchasing an additional 60,000 shares during the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.